Company news

Oragenics Inc. news in 2025

Oragenics Inc.'s news releases, calls and decks from 2025, newest first.

View company

Oragenics Q3 2025 Shareholder Update

November 12, 2025

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

October 21, 2025

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

October 7, 2025

Oragenics Q2 2025 Shareholder Update

August 11, 2025

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

July 31, 2025

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

July 16, 2025

Oragenics Completes Approximately $16.5 Million Offering

July 2, 2025

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

July 1, 2025

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

June 10, 2025

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

May 28, 2025

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025

Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference

April 23, 2025

Decks in 2025